Showing results (21-30 of 829) with videos related to
Sort By:
Pageof 83
Proteomics. Clinical Applications|January 12, 2019
Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future PerspectivesFrederik Persson, Peter RossingUgeskrift for Laeger|September 14, 2012
[Renal disease by type 2 diabetes]Frederik Persson, Peter RossingNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 10, 2011
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trialLian Engelen, Frederik Persson, Isabel Ferreira, et al.Diabetes Care|July 27, 2011
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trialMerel E Hellemons, Frederik Persson, Stephan J L Bakker, et al.Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation|January 4, 2011
Serum uric acid as a new player in the development of diabetic nephropathyPeter Hovind, Peter Rossing, Richard J Johnson, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|October 31, 2012
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney diseaseStine E Nielsen, Katrine J Schjoedt, Kasper Rossing, et al.Diabetologia|July 7, 2017
Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuriaEmilie H Zobel, Bernt Johan von Scholten, Henrik Reinhard, et al.Diabetes Care|April 2, 2010
Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathyMaria Lajer, Anders Jorsal, Lise Tarnow, et al.BMC Nephrology|November 3, 2010
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuriaSten Andersen, Harald Mischak, Petra Zürbig, et al.Kidney International|August 26, 2004
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathyPeter Hovind, Lise Tarnow, Peter Rossing, et al.Pageof 83